RESEARCH TRIANGLE PARK, North Carolina, March 24, 2022 (GLOBE NEWSWIRE) — Opticyte® Amniotic Ocular Matrix, a product from Research Triangle Park-based Merakris Therapeutics, has caught the eye of a leading trade publication for optometrists.
The innovative eye care therapy creates a biological barrier to protect the surface of the cornea – the transparent outer layer at the front of the eyeball – during healing. Merakris said Opticyte Matrix also promotes cell attachment and growth and is commonly used as an additional protective barrier in patients with dry eye and other corneal defects.
The latest edition of Modern optometry highlights the study of a patient with a history of severe dry eye, filamentous keratitis, and treatment-resistant epithelial erosions, whose symptoms resolved with the use of Opticyte Matrix in combination with other therapies. The use of amniotic membrane technologies is used more frequently to treat non-healing corneal defects, according to the study.
“The case report presented in Modern optometry provides further evidence of the efficacy of Opticyte Matrix as a potential treatment for a variety of debilitating and potentially serious eye conditions,” said Chris Broderick, CEO of Merakris. “We are delighted to be included in a publication widely read and respected by eyecare professionals.”
Opticyte is derived from the amniotic membrane, or amnion, the innermost layer of the placenta. The tissue, which can promote healing, is donated by consenting mothers after a caesarean section. Opticyte Matrix is available in several different shapes and sizes to meet a variety of clinical and surgical treatment applications.
Merakris recently partnered with Miracles In Sight (MIS) – originally known as the North Carolina Eye Bank – to provide Opticyte to eye doctors in North Carolina, South Carolina and Texas. The organization, one of the largest nonprofit eye banks in the world, is partnered with 70 eye clinics in the tri-states who will have immediate access to the product under the agreement.
Founded in 2016, Merakris Therapeutics is a leader in the research, development and commercialization of regenerative health products. The company is a pioneer in the use of technologies derived from birth tissue that protect and promote healing of damaged tissue. In addition to Opticyte Matrix, its products include:
Dermacyte Amniotic Wound Care Liquid, a non-cellular sterile filtered amniotic injection that promotes wound healing; and
Dermacyte Amniotic Wound Care Matrix, an allograft of human amniotic membrane tissue that provides protective coverage for skin wounds and surgical sites.
Merakris is also investigating other new biotechnology solutions that promote wound healing and skin rejuvenation.
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These include projections and estimates regarding the marketing and other potentials of Merakris’ products, or regarding the future revenue potential of such products. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Merakris management believes that the forward-looking statements contained in this press release are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond our control. of Merakris. , which could cause actual results and developments to differ materially from those expressed, implied or projected by the forward-looking information and statements. These risks and uncertainties include, among others, unexpected regulatory actions or delays or government regulation generally that could affect the availability or commercial potential of the product; the fact that the product may not be commercially successful; uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product; post-marketing, unexpected safety, quality or manufacturing issues, competition generally, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation; and volatile economic and market conditions that may impact us, our employees, advisers, customers, suppliers, vendors or other business partners – and the financial condition of any of them – as well as the global economy as a whole.
CONTACT: Otter Creek Communications (973) 590-9537 [email protected]